In conclusion, these results suggested that clinical monoclonal antibody nivolumab targeting PD-1 plays the role in PD-1 gene regulation, and they also proved PD-1 depletion by nivolumab treatment promotes CRC tumor growth in vitro and in vivo. Here, PDCD1 is linked to colorectal carcinoma.